ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $511.09 ($507.84–$514.96, $4.86M total) across 8 trades on 2026-08-31 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO’s sale reduces her ownership but follows a pre‑arranged plan, suggesting limited new information for the market.
Market read
Insider sale provides modest new data for traders; likely limited price effect.
What to watch
Potential upcoming clinical data releases or partnership announcements could offset the sale’s impact.
Background
Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
CEO Martine A. Rothblatt sold 9,500 shares for $4.9M via a 10b5‑1 plan, reducing her stake to 324,443 shares.
Modest downward pressure on UTHR price in the next few days.
The sale size ($4.9M) is material for a mid‑cap biotech, but the insider used a pre‑arranged plan, limiting informational content.
Market effects
May prompt analysts to reassess insider sentiment in the biotech/therapeutics sector.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond UTHR shareholders.
Counterpoint
The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect negative outlook; price could remain stable.
Key entities
- CompanyUnited Therapeutics Corp
Biopharmaceutical company developing therapies for pulmonary arterial hypertension and other conditions.
- ExecutiveMartine A. Rothblatt
Chairperson & CEO of United Therapeutics.
